Botulinum toxin treatment for esophageal achalasia

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation
Botulinum toxin treatment for esophageal achalasia. Lansdale: HAYES, Inc.. Directory Publication. 2010

Authors' objectives
Botulinum toxin (BTX) is used for the endoscopic treatment of esophageal achalasia, characterized by sphincteric spasticity. BTX is injected directly into the lower esophageal sphincter in order to produce chemical denervation of the abnormally functioning muscles by blocking synaptic transmission. This relaxes the muscle and causes a temporary relief of pain and other symptoms.

Final publication URL
The report may be purchased from:http://www.hayesinc.com/hayes/crd/?crd=11817

Indexing Status
Subject indexing assigned by CRD

MeSH
Botulinum Toxins; Esophageal Achalasias

Language Published
English

Country of organisation
United States

English summary
An English language summary is available.

Address for correspondence
HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com

AccessionNumber
32011000879

Date abstract record published
22/06/2011